Placebo matching nerandomilast

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

1 competitor in Interstitial Lung Diseases

#DrugCompanyPhaseTrials

1

Jascayd

Boehringer Ingelheim

Phase 3

22

Placebo matching nerandomilast

Boehringer Ingelheim

Phase 3

2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Interstitial Lung Diseases2 trials

A Double Blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nerandomilast Over at Least 26 Weeks in Patients With Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases (SARD-ILD)

Recruiting·Boehringer Ingelheim·Phase 3·NCT06806592·400 enrolled

A Double-blind, Randomized, Placebo-controlled Trial Investigating the Efficacy and Safety of Nerandomilast Over at Least 52 Weeks in Patients With Fibrosing Interstitial Lung Disease at Risk for Disease Progression (FIBRONEER-ACT)

Not yet recruiting·Boehringer Ingelheim·Phase 3·NCT07540988·466 enrolled

Details

Drug Info

Related News